In patients with chronic hepatitis C, ribavirin doses of vitamin D and alpha -2 pegeuinteoperon impact on response to treatment A: randomized, multicenter, phase IV clinical public

Hanyang University Seoul Hospital0 个研究点目标入组 222 人开始时间: 待定最近更新: 2019年3月11日

适应症

试验速览

暂无简介。

•(1) Men and women age 20 to 75 years
•(2) HCV-RNA PCR positive for a (quantitative examination> 50 IU / mL)
•(3) within the past year, the visual inspection undertaken between (liver imaging) excludes from the hepatocellular carcinoma cases (tabyeongwoneseo conducted if test results are acceptable)
•(4) If normal pretreatment serum calcium concentration

•1) factors of HCC diagnosis, or treatment (more than six months after treatment, but recurrence of liver cancer if not included)
•(2) decompensated cirrhosis (non-decompensated liver function boyineunja)
•(3) the absolute hojunggusu <750 cells/mm3 or a platelet count> 50,000 cells/mm3
•(4) in screening serum creatinine> 1.5 x normal upper limit
•(5) a history of severe mental illness, particularly depression, major depression, severe mental illness or mental illness, suicide attempts, hospitalization for mental illness or mental disability, due to the mean over a period of time.
•(6) bugapseongseon disease
•(7) prescription drugs that are not well controlled by the thyroid
•(8) HBV or HIV infected people diagnosed concurrent
•(9), hepatocellular carcinoma treated with non-malignant character than two (2) years after the decision is not no cure Now
•(10) and other clinical trials, when the head judge to perform the clinical trials, patients that are considered difficult to

发起方

Hanyang University Seoul Hospital